Back

Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Emerging lipid-lowering therapeutic modalities Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Sayeli Elisa Martinez-Topete

Tijuana (Mexico)

5 More presentations in this session

Presentation thumbnail
Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044
Ms S. Nilsson (Gothenburg, SE)
Abstract
Presentation thumbnail
RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides
Doctor B. Buot (Quezon City, PH)
Abstract
Presentation thumbnail
Comparative effectiveness of probucol versus ezetimibe in statin-treated patients with established atherosclerotic cardiovascular disease
Doctor L. Liu (Tianjin, CN)
Abstract
Presentation thumbnail
Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
Doctor E. Stroes (Amsterdam, NL)
Abstract
Presentation thumbnail
Evolocumab early reduces Interleukin-1β/Interleukin-17A and improves left ventricular function in ST-segment elevation myocardial infarction: an observational study in the real world
Professor J. Gao (Tianjin, CN)
Abstract

Access the full session

Session thumbnail
Emerging lipid-lowering therapeutic modalities

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
30 August 2025
thumbnail
Congress Presentation
Association between dose of medications and mortality in heart failure with reduced ejection fraction: a systematic review and dose-response meta-analysis
20 May 2023
thumbnail
Congress Presentation
Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and lipid-lowering therapy intensity in cardiovascular disease patients
29 August 2025
thumbnail
Congress Presentation
Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources